Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Artelo Biosciences, Inc. Common Stock

ARTL

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.65 – $1.75
Volume 16,429
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$931.22K
Price / earnings
—
Price / book
0.15×
Price / sales
—
EV / sales
—
EV / EBITDA
0.36×

Profitability

Earnings per share
-$20.66
Return on assets
-169.57%
Return on equity
-181.51%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10.47×
Quick ratio
10.47×
Cash ratio
10.11×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.76M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ARTL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$989K$1.63M$1.92M$1.89M$1.81M$1.28M$995K$1.34M
Research and development$803K$876K$773K$893K$1.28M$1.87M$1.38M$2.48M
Total operating expenses$1.79M$2.51M$2.69M$2.79M$3.09M$3.15M$2.38M$3.81M
Operating income-$1.79M-$2.51M-$2.69M-$2.79M-$3.09M-$3.15M-$2.38M-$3.81M
Interest expense$0-$6K-$124K-$94K-$111K-$72K$0$0
Income before taxes-$1.77M-$2.43M-$2.96M-$4.17M-$3.12M-$3.22M-$2.37M-$3.78M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.77M-$2.43M-$2.96M-$4.17M-$3.12M-$3.22M-$2.37M-$3.78M
Net income attributable to common shareholders-$1.77M-$2.43M-$2.96M-$4.17M-$3.12M-$3.22M-$2.37M-$3.78M
EBITDA-$1.79M-$2.51M-$2.69M-$2.79M-$3.09M-$3.15M-$2.38M-$3.81M
Basic earnings per share-$3.19-$8.01-$36.00-$51.39-$88.80-$151.74-$112.95-$189.19
Diluted earnings per share-$3.19-$8.01-$36.00-$51.39-$88.80-$151.74-$112.95-$189.19

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Artelo Biosciences, a clinical-stage pharmaceutical company, has priced a public offering of 441,210 common stock shares and pre-funded warrants, expecting to raise approximately $2.0 million to support its therapeutic development efforts.

GlobeNewswire Inc.

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 31, 20261-for-9reverse split
Mar 10, 20261-for-3reverse split
Jun 13, 20251-for-6reverse split
Aug 10, 20221-for-15reverse split
Jun 21, 20191-for-8reverse split